登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、及时、完整，没有虚假记载、误导性陈述或 重大遗漏。 广东凯普生物科技股份有限公司（以下简称"公司"）于2025年8月26日在巨潮资讯网 （http://www.cninfo.com.cn）披露了《关于召开2025年第一次临时股东大会通知的公告》（公告编号： 2025-048），公司将于2025年9月10日（星期三）15:00召开2025年第一次临时股东大会。本次股东大会 将采取现场投票和网络投票相结合的方式召开，根据相关规定，现将有关事项再次提示如下： 一、召开会议的基本情况 1、股东大会届次：2025年第一次临时股东大会 5、会议召开方式：现场表决和网络投票相结合的方式。 （1）现场表决：股东本人出席现场会议或者通过授权委托书（见附件一）委托他人出席现场会议并进 行表决； （2）网络投票：股东在本公告公布的网络投票时间内，登录深交所交易系统或深交所互联网投票系统 （http://wltp.cninfo.com.cn）进行表决。 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：公司于2025年8 ...

证券代码：300639 证券简称：凯普生物 公告编号：2025-051 广东凯普生物科技股份有限公司 关于召开 2025 年第一次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、及时、完整，没 有虚假记载、误导性陈述或重大遗漏。 广东凯普生物科技股份有限公司（以下简称"公司"）于2025年8月26日在巨 潮资讯网（http://www.cninfo.com.cn）披露了《关于召开2025年第一次临时股东 大会通知的公告》（公告编号：2025-048），公司将于2025年9月10日（星期三） 相结合的方式召开，根据相关规定，现将有关事项再次提示如下： 一、召开会议的基本情况 第二十九次会议审议通过了《关于召开 2025 年第一次临时股东大会的议案》。本次 会议的召集程序符合有关法律、法规和《广东凯普生物科技股份有限公司章程》的 有关规定。 （1）现场会议召开时间：2025 年 9 月 10 日（星期三）15:00 （2）网络投票时间： ①深圳证券交易所（以下简称"深交所"）交易系统网络投票时间：2025 年 9 月 10 日 9:15 至 9:25；9:30 至 11:30；13: ...

证券代码：300639 证券简称：凯普生物 公告编号：2025-051 广东凯普生物科技股份有限公司 广东凯普生物科技股份有限公司（以下简称"公司"）于2025年8月26日在巨 潮资讯网（http://www.cninfo.com.cn）披露了《关于召开2025年第一次临时股东 大会通知的公告》（公告编号：2025-048），公司将于2025年9月10日（星期三） 15:00召开2025年第一次临时股东大会。本次股东大会将采取现场投票和网络投票 相结合的方式召开，根据相关规定，现将有关事项再次提示如下： 一、召开会议的基本情况 1、股东大会届次：2025 年第一次临时股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：公司于 2025 年 8 月 25 日召开的第五届董事会 第二十九次会议审议通过了《关于召开 2025 年第一次临时股东大会的议案》。本次 会议的召集程序符合有关法律、法规和《广东凯普生物科技股份有限公司章程》的 有关规定。 4、会议召开时间： （1）现场会议召开时间：2025 年 9 月 10 日（星期三）15:00 （2）网络投票时间： ①深圳证券交易所（以下简称"深交所 ...

Group 1 - The company, Capbio, announced the acquisition of two invention patents on August 2025 [2] - One patent pertains to the biotechnology field, specifically for detecting antibiotic resistance genes in reproductive tract pathogens [2] - The other patent relates to genetic testing technology, focusing on a primer composition for detecting SNP loci associated with antipsychotic medications [2]

证券代码：300639 证券简称：凯普生物 公告编号：2025-050 个 SNP 位点进行灵敏、特异地检测的引物组合物,并利用所述引物组合物构建得到了相 应的试剂盒。利用本发明所述引物组合物或所述试剂盒,可结合飞行时间质谱检测所述 18 个 SNP 位点,依据 SNP 位点检测情况指导抗精神病药的个性化用药,避免出现用药无 反应以及会出现严重副作用等情况,有利于精神分裂症等精神病的治疗。 公司持续向"核酸分子诊断龙头企业"的大目标迈进，持续推进"核酸 99"战略， 促进公司产品结构的不断丰富，满足市场多样化的需求。上述发明专利权的取得符合公 司发展战略规划，不会对公司目前的经营状况产生重大的影响，但有利于进一步完善公 司的知识产权体系，充分发挥公司的知识产权优势，丰富公司产品体系，提升公司的核 心竞争力。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述 或者重大遗漏。 广东凯普生物科技股份有限公司（以下简称"凯普生物"或"公司"）以及子公司 在 2025 年 8 月获得发明专利授权情况如下： | 序号 | 发明专利名称 | 专利号 | 专利类型 | 授予国家/地区 | 专 ...

Core Insights - The company, Capstone Bio (300639), reported that as of August 20, 2025, the total number of shareholders is 29,679 [1] Company Summary - Capstone Bio has engaged with investors through an interactive platform, providing updates on shareholder numbers [1] - The company is actively communicating with its investors, indicating a focus on transparency and shareholder engagement [1]

Core Insights - The company reported a significant decline in revenue and net profit for the first half of 2025, with total revenue of 315 million yuan, down 22.96% year-on-year, and a net loss of 89.59 million yuan, a decrease of 16.46% compared to the previous year [1][10] Financial Performance - Total revenue for the second quarter was 181 million yuan, reflecting a year-on-year decrease of 19.87% [1] - The gross profit margin decreased to 46.98%, down 12.42% year-on-year, while the net profit margin fell to -43.53%, a decline of 37.6% [1] - The company's total expenses (selling, administrative, and financial) amounted to 170 million yuan, accounting for 54.0% of revenue, a decrease of 7.09% year-on-year [1] - Earnings per share were reported at -0.14 yuan, a decrease of 17.15% year-on-year [1] Balance Sheet Changes - Cash and cash equivalents increased by 31.56% due to the maturity of large deposits [3] - Accounts receivable decreased by 46.05%, indicating a reduction in receivables [3] - Long-term borrowings increased by 80.98%, attributed to share repurchase financing [6] Operational Insights - The company’s business model relies heavily on research and marketing, necessitating a thorough examination of the underlying drivers of these operations [12] - The company has experienced a historical median ROIC of 16.79%, with the worst year being 2024, which recorded a ROIC of -20.91% [11]

Core Viewpoint - Capbio (300639.SZ) reported its semi-annual results for 2025, highlighting the current institutional investor holdings and changes in ownership structure [1] Summary by Relevant Sections - Institutional Holdings - As of August 25, 2025, four institutional investors disclosed holdings in Capbio A-shares, totaling 279 million shares, which represents 43.12% of Capbio's total share capital [1] - The institutional investors include Hong Kong Science and Technology Venture Capital Co., Ltd., Yunnan Zhonghe Enterprise Management Co., Ltd., Shenzhen Guodiao Investment Fund Partnership (Limited Partnership), and Yunnan Yancheng Enterprise Management Co., Ltd. [1] - Compared to the previous quarter, the total institutional holding percentage decreased by 0.65 percentage points [1]

Core Viewpoint - The company reported a significant decline in revenue and net profit for the reporting period, primarily due to industry policy adjustments and increased competition in the molecular diagnostics sector, particularly affecting HPV-related products [5][6][11]. Financial Performance - The company achieved operating revenue of 314.99 million yuan, a year-on-year decrease of 22.96% [5]. - The net profit attributable to shareholders was -89.59 million yuan, down 16.46% year-on-year [5]. - The net profit after deducting non-recurring gains and losses was -95.61 million yuan, a decline of 11.63% year-on-year [5]. Business Segments - **Molecular Diagnostics**: Revenue from molecular diagnostic products decreased significantly due to price reductions from centralized procurement policies and an increase in VAT from 3% to 13% starting January 1, 2025 [5][6]. - **Medical Testing Services**: Revenue from medical testing services fell to 91.57 million yuan, down 18.85% year-on-year, leading to operational losses due to high fixed costs [6]. - **Healthcare Services**: The healthcare services segment, particularly the operations of Chaozhou Kaipu Hospital, incurred losses as initial revenues did not cover operational costs [6]. Strategic Initiatives - The company is focusing on three main business areas: molecular diagnostics, medical testing services, and healthcare management, aligning with national strategic development goals [6][9]. - The "Kepu 843 Plan" was introduced to drive growth through eight major project directions, including cervical cancer prevention and personalized medicine [10][12]. Product Development - The company has developed a comprehensive range of HPV testing products, with over 79 million uses reported, and has been recognized for its contributions to cervical cancer screening [10][11]. - The "Four Pillars" product series, including thalassemia and hearing loss susceptibility gene tests, has become a significant revenue contributor outside of HPV products [13]. Quality Control and Innovation - The company has invested over 900 million yuan in R&D since its inception, with 4.15 million yuan allocated in the reporting period, representing 13.18% of revenue [16]. - A robust quality management system has been established, achieving 100% compliance with international quality standards [19]. International Expansion - The company is pursuing internationalization, with 59 CE certifications and patents in multiple countries, aiming to enhance its global presence [24]. Operational Efficiency - The company is implementing cost-reduction measures and optimizing laboratory operations to improve efficiency amid industry challenges [25][28].

Group 1 - The company announced the approval of multiple proposals, including the 2025 semi-annual report and summary [2]